A randomized, open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801/EGF111792)

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorGOMEZ, Henry Leonidas
dc.contributor.authorNECIOSUP, Silvia P.
dc.contributor.authorTOSELLO, Celia
dc.contributor.authorXAVIER, Patricia
dc.contributor.authorNASCIMENTO, Yeni Neron do
dc.contributor.authorFANELLI, Marcelo
dc.contributor.authorISMAEL, Gustavo
dc.contributor.authorBINES, Jose
dc.contributor.authorSAMPAIO, Carlos
dc.contributor.authorLERZO, Guillermo Luis
dc.contributor.authorCAPO, Adolfo Miguel
dc.contributor.authorMANO, Max S.
dc.contributor.authorFEIN, Luis
dc.contributor.authorWERUTSKY, Gustavo
dc.contributor.authorBARRIOS, Carlos H.
dc.date.accessioned2013-10-11T21:18:21Z
dc.date.available2013-10-11T21:18:21Z
dc.date.issued2012
dc.description.abstractBackground: Lapatinib-capecitabine is approved for the treatment of ErbB2-amplified metastatic breast cancer (MBC) after failure to anthracyclines, taxanes and trastuzumab. GLICO-0801 evaluates different lapatinib-based chemotherapy combinations as 1st/2nd line treatment for ErbB2 amplified MBC progressing after taxane treatment. We present the results of a planned safety interim analysis. Methods: This is an open-label, randomized, international, phase II trial exploring lapatinib (L) 1250mg qd in combination with capecitabine 2000mg/m2 d 1-14 (Arm A) or vinorelbine 25mg/m2 d 1 and 8 (Arm B) or gemcitabine 1000mg/m2 d 1 and 8 (Arm C). Primary objective is to determine the clinical benefit rate (defined as CR+PR+SD for ≥24 weeks). This trial is registered at www.clinicaltrials.gov number: NCT01050322 Results: The first83 randomized patients (pts) (Arm A=29, B=28 and C=26) were included in this analysis. Of them, 65 (78%) have discontinued therapy with mean number of cycles of 4.7, 6.2 and 7.5 in arms A, B and C respectively. Eighteen (21%) pts are still on treatment. Median age was 52y (29-84); 80 pts (96%) had PS 0-1; 51 (61%) were postmenopausal. Fifty-six pts (67%) had visceral metastasis, 52 (63%) were treated as 2nd line therapy and 36 (43%) had received prior trastuzumab. Most reported adverse events (AE) (87%) were grade 1-2. The most common AE (any grade) in arm A: diarrhea 72%, hand-foot syndrome 45%, vomiting 39%, anemia 36%; in arm B: diarrhea 75%, neutropenia 68%, nausea 43%, vomiting 39%; in arm C: diarrhea 72%, neutropenia 60%, anemia 44%, increase in ALT 44%. The most frequent serious AE reported in arm A: diarrhea in 3 pts (10%) and thrombocytopenia in 2 pts (7%); in arm B: febrile neutropenia in 2 pts (7%) and in arm C: sepsis in 1 pt (4%). There was one toxic death related to chemotherapy in arm C. Conclusions: There were no unexpected toxicities so far in this trial with most AEs being mild to moderate and manageable. This interim analysis supports the continuation of the study.
dc.description.conferencedateJUN 01-06, 2012
dc.description.conferencelocalChicago - IL, EUA
dc.description.conferencename48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
dc.description.indexMEDLINE
dc.identifier.citationJOURNAL OF CLINICAL ONCOLOGY, v.30, n.15, suppl.S, 2012
dc.identifier.issn0732-183X
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/2833
dc.language.isoeng
dc.publisherAMER SOC CLINICAL ONCOLOGY
dc.relation.ispartofJournal of Clinical Oncology
dc.rightsrestrictedAccess
dc.rights.holderCopyright AMER SOC CLINICAL ONCOLOGY
dc.subject.wosOncology
dc.titleA randomized, open-label, phase II study of lapatinib/capecitabine, lapatinib/vinorelbine, or lapatinib/gemcitabine in patients with ErbB2-amplified metastatic breast cancer progressing after taxane treatment: Results of an interim analysis (GLICO-0801/EGF111792)
dc.typeconferenceObject
dc.type.categorymeeting abstract
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.contributor.author-fmusphcMAX SENNA MANO
hcfmusp.description.issue15
hcfmusp.description.issuesuppl S
hcfmusp.description.volume30
hcfmusp.origemWOS
hcfmusp.origem.wosWOS:000318009800170
hcfmusp.publisher.cityALEXANDRIA
hcfmusp.publisher.countryUSA
relation.isAuthorOfPublication1541ce2f-dafd-4094-b650-ef95fa7da1e3
relation.isAuthorOfPublication.latestForDiscovery1541ce2f-dafd-4094-b650-ef95fa7da1e3
Arquivos
Coleções
Comunicações em Eventos - FM/MDR
Comunicações em Eventos - HC/ICESP
Comunicações em Eventos - LIM/24